Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MESO vs CLDX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MESO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 3–5 Matrix Metrics)

MESO Overall Winner 6-Pillar Tally: MESO 4 – 1 CLDX (1 Tie) Matrix Metrics: MESO 3 – 5 CLDX

As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Celldex Therapeutics, Inc (CLDX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas CLDX carries 55.7/100 (HOLD) at $28.68 (N/M Forward P/E, -211684.8% operating margin).

  • Composite vs. Pillar Nuance: While CLDX currently prints a higher short-term Unified Composite Score (55.7/100 HOLD vs. MESO 34.6/100 SELL), MESO captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -211684.8% operating margin) and revenue trajectory (+390.7% vs. -97.0% YoY).
  • Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile CLDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MESO vs CLDX
MESO NASDAQ Head-to-Head Winner
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $13.64 · SMA50: $14.22
CLDX NASDAQ
Celldex Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$28.68
-0.52% 1D
Market Cap $2.2B
TTM Revenue $158,000
Forward P/E N/M
Beta / 30D Vol 1.05β · 45% Vol
Unified Composite Score
55.7 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.6%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $29.62 · SMA50: $31.76

6-Pillar Scorecard Institutional Category Breakdown (MESO 4 – 1 CLDX)

Columns: Metric · MESO · CLDX
1. Valuation Multiples MESO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 14.1x N/M
2. Growth & Scale MESO
Revenue Growth (YoY) +390.7% -97.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $120M $158,000
Market Cap $1.7B $2.2B
3. Profitability & Quality MESO
Gross Margin 80.0% N/A
Operating Margin -42.6% -211684.8%
Net Profit Margin -47.8% 0.0%
Return on Equity (ROE) -9.9% -49.5%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$45M EBITDA -$260M
Cash Flow Margin -37.1% EBITDA Mgn N/A
Net Cash / Leverage $4.38 Book/Sh · -9.9% ROE $17M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CLDX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 76.8% (37th %ile) 134.4% (56th %ile)
Put/Call OI Skew Thin ADR Chain 0.70x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MESO (3) vs CLDX (5)
Institutional Metric MESO CLDX Criterion Row Edge
Market Capitalization
Scale
$1.7B $2.2B Larger Scale CLDX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+390.7% -97.0% Higher Growth MESO
Operating Margin (TTM)
Profitability
-42.6% -211684.8% Higher Margin MESO
Net Profit Margin
Profitability
-47.8% 0.0% Higher Margin CLDX
Return on Equity (ROE)
Capital Efficiency
-9.9% -49.5% Higher ROE MESO
52-Week Range Position
Momentum
6% ($12–$22) 28% ($22–$45) Stronger Trend CLDX
Beta / 30D Volatility
Risk Regime
1.18β · 78% Vol 1.05β · 45% Vol Lower Realized Risk CLDX
Unified Institutional Score
Composite Signal
34.6 / 100 (SELL) 55.7 / 100 (HOLD) Higher Composite CLDX
Trailing 12M Revenue (USD)
Operating Scale
$120M $158,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) -$260M ($17M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLDX +10.28 pp
MESO: -6.1% · CLDX: +4.18%
3M Horizon MESO +6.18 pp
MESO: -25.19% · CLDX: -31.37%
6M Horizon CLDX +9.72 pp
MESO: -14.82% · CLDX: -5.1%
1Y Horizon CLDX +37.33 pp
MESO: -16.42% · CLDX: +20.91%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs CLDX. Trailing 12-month operating profitability (MESO -42.6% vs CLDX -211684.8%) and valuation multiples (MESO N/M vs CLDX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M
CLDX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$158,000
Gross MarginN/A
Op. Margin-211684.8%
ROE / Fwd P/E-49.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLDX BREAKDOWN
67d in phase · OBV NEUTRAL
Current IV 134.4%
IV Percentile 56th %ile
Put/Call OI Skew 0.70x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CLDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLDX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -211684.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MESO vs CLDX Key Questions & Quantitative Answers

As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Celldex Therapeutics, Inc (CLDX) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas CLDX carries 55.7/100 (HOLD) at $28.68 (N/M Forward P/E, -211684.8% operating margin). Composite vs. Pillar Nuance: While CLDX currently prints a higher short-term Unified Composite Score (55.7/100 HOLD vs. MESO 34.6/100 SELL), MESO captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -211684.8% operating margin) and revenue trajectory (+390.7% vs. -97.0% YoY). Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile CLDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with CLDX at -97.0% YoY revenue growth and +0.0% YoY earnings growth on $158,000 TTM revenue (N/A gross margin, -211684.8% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $158,000 for CLDX. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLDX.

MESO screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas CLDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus CLDX (-49.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, CLDX carries 134.4% implied volatility (56th %ile, Balanced (25th–60th %ile)), a 0.70x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.05β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.